



• EDITORIAL, p 7  
• PERSONAL VIEW, p 26

## NEWS

- 1 GPs are urged to report adverse drug reactions after a 37% slump in number of reports  
*Genzyme restores some access to multiple sclerosis drug after neurologists protest*
- 2 GSK fights claims from UK patients who took rosiglitazone  
*Lancet* withdraws its support of document on collaboration between doctors and drug industry
- 3 GPs spot 80% of cancers within two consultations  
Two NHS trusts could fail owing to "catastrophic mistakes," warn MPs
- 4 Hackney GPs are told they cannot opt in to provide out of hours care  
Lewisham's emergency unit will be downgraded, health secretary says  
Measles outbreak hits northeast England
- 5 GMC says doctors can give records to patients thinking of suicide
- 6 Only one doctor is left working in rebel controlled Nuba Mountains  
NICE is likely "to take blame" as healthcare budgets tighten, chairman says



GPs refer suspected cancer more promptly than thought, p 3

## RESEARCH

### RESEARCH NEWS

- 11 All you need to read in the other general journals

### RESEARCH PAPERS

- 12 Use of dietary linoleic acid for secondary prevention of coronary heart disease and death: evaluation of recovered data from the Sydney Diet Heart Study and updated meta-analysis  
Christopher E Ramsden et al  
• EDITORIAL, p 8
- 13 Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis  
Alexander Y Valley et al
- 14 Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data  
Yana Vinogradova et al
- 15 QT interval and antidepressant use: a cross sectional study of electronic health records  
Victor M Castro et al

Articles appearing in this print journal have already been published on [bmj.com](http://bmj.com), and the version in print may have been shortened. [bmj.com](http://bmj.com) also contains material that is supplementary to articles: this will be indicated in the text (references are given as w1, w2, etc) and be labelled as extra on [bmj.com](http://bmj.com).

Please cite all articles by year, volume, and elocator (rather than page number), eg *BMJ* 2013; 346:f286.

A note on how to cite each article appears at the end of each article, and this is the form the reference will take in PubMed and other indexes.

## COMMENT

### EDITORIALS

- 7 Is there a cure for corporate crime in the drug industry?  
Courtney Davis and John Abraham
- 8 American Heart Association advice on omega 6 PUFAs cast into doubt  
Philip C Calder  
• RESEARCH, p 12
- 9 Tamiflu: 14 flu seasons and still questions  
Harlan M Krumholz et al



At best, Tamiflu shortens duration of symptoms by a day, p 9

- 10 Where next for evidence based healthcare  
Carl Heneghan and Fiona Godlee

### FEATURES

- 16 Who knew what, and when, at Mid Staffs?

The Francis report into the appalling failings of care at Mid Staffordshire NHS Trust has finally been published. Philip Carter and Brian Jarman explain how events unfolded



Insights into the problems on Stafford Hospital's wards, p 16

### ANALYSIS

- 20 Cutting premature death in Rwanda  
Rwanda's successes in delivering healthcare despite its history of conflict and consequent poverty offer lessons to other poor countries, say Paul Farmer and colleagues



Joseph Edward Murray, p 27

## COMMENT

## LETTERS

23 Sentinel node biopsy for melanoma; Trial registration and publication

24 How to act when you should; Sledging injuries

## OBSERVATIONS

## MID STAFFS INQUIRY

25 Mid Staffs shows what's wrong with NHS management

Heather Wood

## PERSONAL VIEW

26 Big pharma often commits corporate crime, and this must be stopped

Peter C Gøtzsche



Tackling drug companies' illicit activities, p 26

## OBITUARIES

27 Joseph Edward Murray

Nobel prize winner whose interest in the biology of tissue and organ transplantation arose from his military experience

## OBITUARIES

28 Mary Adams Hunter; Peter Francis Kennedy; Keith Danford Roberts; Frank Clifford Rose; Bryan Ogle Scott; David Bryan Stuart Taylor; Eileen Wilson

## LAST WORDS

42 Imagine all the people Des Spence

End the silence on animal products in drugs

Kinesh Patel

## EDUCATION

## CLINICAL REVIEW

29 Ulcerative colitis

Alexander C Ford et al

## PRACTICE

## RATIONAL IMAGING

35 Investigating urinary tract infections in children

A Davis et al

## ENDGAMES

38 Quiz page for doctors in training

## MINERVA

40 "Sweating sickness" in Tudor England, and other stories



A life threatening drug reaction, p 40

Too much information and not enough time?

BMJ Masterclasses

[masterclasses.bmj.com](http://masterclasses.bmj.com)



9 February 2013 Vol 346

The Editor, *BMJ*  
 BMA House, Tavistock Square,  
 London WC1H 9JR  
 Email: editor@bmj.com  
 Tel: +44 (0)20 7387 4410  
 Fax: +44 (0)20 7383 6418  
**BMA MEMBERS' INQUIRIES**  
 Email: membership@bma.org.uk  
 Tel: +44 (0)20 7383 6642  
**BMJ CAREERS ADVERTISING**  
 Email: sales@bmjcareers.com  
 Tel: +44 (0)20 7383 6531  
**DISPLAY ADVERTISING**  
 Email: sales@bmjgroup.com  
 Tel: +44 (0)20 7383 6386  
**REPRINTS**  
 UK/Rest of world  
 Email: ngurneyrandall@bmjgroup.com  
 Tel: +44 (0)20 8445 5825  
 USA  
 Email: mfogler@medicalreprints.com  
 Tel: +1 (856) 489 4446  
**SUBSCRIPTIONS**  
 BMA Members  
 Email: membership@bma.org.uk  
 Tel: +44 (0)20 7383 6642  
 Non-BMA Members  
 Email: support@bmjgroup.com  
 Tel: +44 (0)20 7383 6270  
**OTHER RESOURCES**  
 For all other contacts:  
[resources.bmj.com/bmj/contact-us](http://resources.bmj.com/bmj/contact-us)  
 For advice to authors:  
[resources.bmj.com/bmj/authors](http://resources.bmj.com/bmj/authors)  
 To submit an article:  
[submit.bmj.com](http://submit.bmj.com)



The *BMJ* is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association.

The BMA grants editorial freedom to the Editor of the *BMJ*. The views expressed in the journal are those of the authors and may not necessarily comply with BMA policy. The *BMJ* follows guidelines on editorial independence produced by the World Association of Medical Editors ([www.wame.org/wamestmt.htm#independence](http://www.wame.org/wamestmt.htm#independence)) and the code on good publication practice produced by the Committee on Publication Ethics ([www.publicationethics.org.uk/guidelines/](http://www.publicationethics.org.uk/guidelines/)).

The *BMJ* is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group, or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement.

To the fullest extent permitted by law, the BMJ Publishing Group shall not be liable for any loss, injury, or damage resulting from the use of the *BMJ* or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

©BMJ Publishing Group Ltd 2012  
 All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any other means, electronic, mechanical, photocopying, recording, or otherwise, without prior permission, in writing, of the *BMJ*.

Published weekly. US periodicals class postage paid at Rahway, NJ. Postmaster: send address changes to *BMJ*, c/o Mercury Airfreight International Ltd Inc, 365 Blair Road, Avenel, NJ 07001, USA. \$796.

Weekly

Printed by Pester Limited



DAN KITWOOD/GETTY IMAGES

## PICTURE OF THE WEEK

The formal identification this week of skeletal remains unearthed in a Leicester car park as those of King Richard III has reignited discussion over his disabilities, which have long fascinated medical historians, including in the pages of the *BMJ* ("Physical deformity of Richard III" (*BMJ* 1977;2:1650-2). Examination of the remains confirmed the existence of scoliosis, which led to his "hunched" reputation, but showed no indication of the withered arm mentioned by Shakespeare.

## RESPONSE OF THE WEEK

An unknown affecting prostate cancer treatment decisions for younger patients is knowledge of the range of timescales for the disease to evolve. Molecular-clock techniques have recently determined timescales for the development of pancreatic cancer (*Nature* 2010;467:114). Is application of these techniques not a "future research need" for prostate cancer?

William Tobin, retired university lecturer, Vannes, France, in response to "Prostate cancer screening and the management of clinically localized disease" (*BMJ* 2013;346:f325)

## MOST SHARED

Drug-grapefruit juice interactions  
 How science is going sour on sugar  
 Science souring on sugar  
 Benefits of cancer screening take years to appreciate  
 Case can proceed against doctor who discussed patient's details on train, say judges

## BMJ.COM POLL

Last week's poll asked:  
 "Would you encourage your patients to have prostate specific antigen testing?"

**54%** voted no  
 (total 961 votes cast)

► *BMJ* 2012;346:f325

This week's poll asks:

"Will the Francis report lead to improvements in patient care?"

► **Vote now on [bmj.com](http://bmj.com)**



## EDITOR'S CHOICE

## A winter of discontent

**"The horrors of Stafford Hospital were failures of clinical care—but these were the symptoms ... of a serious underlying illness"**

► To receive Editor's Choice by email each week, visit [www.bmj.com/newaccount](http://www.bmj.com/newaccount)

## Twitter

► Follow the editor, Fiona Godlee, at [twitter.com/fgodlee](http://twitter.com/fgodlee), and the *BMJ* at [twitter.com/bmj\\_latest](http://twitter.com/bmj_latest)



## Sign up today using your smartphone

—follow these steps:

- Download a free QR reader from your handset's app store
- Hold your smartphone over the QR code
- You will then be forwarded to the email sign up page

"The disconnect between the drug industry's proclamations—of the 'highest ethical standards,' of 'following ... all legal requirements,' and providing 'most accurate information available regarding prescription medicines'—and the reality of the conduct of big pharma is vast." So says Peter C Gøtzsche, director of the Nordic Cochrane Centre, in his Personal View article this week (p 26). His is an outspoken attack on drug company malfeasance, which he identifies as illegal marketing (the subject of a recent feature by Ed Silverman (*BMJ* 2013;346:f320)), misrepresentation of research results, hiding data on harms, and—in the United States—Medicare and Medicaid fraud. Gøtzsche says, "As the crimes were widespread and repetitive, they are probably committed deliberately—because crime pays." And indeed the sums that he says are involved are staggering, as are the consequences of the crimes, "including the unnecessary deaths of thousands of people and many billions in losses for our national economies."

Moreover, says Gøtzsche, "doctors are often complicit in these crimes, as kickbacks and other forms of corruption were common; they were induced to use expensive drugs and paid to lend their names to ghostwritten articles to show that a drug works for unapproved conditions."

The *BMJ* has a strong track record of exposing and reporting on pharma's dirty tricks. And when it has been merited we have also recognised the enormous good that drug companies have done and continue to do. Initiatives such as Regulation 658/2007 in the European Union—which empowers the EU Commission to impose fines on firms that violate EU legislation on medicines—and US Sunshine Act legislation—requiring

drug companies to declare all payments and hospitality they give to doctors—may seem to herald a bright new day. But Gøtzsche's argument suggests that the skies are still dark, as does a linked editorial by Courtney Davis and John Abraham (p 7).

Gøtzsche calls for tougher sanctions, including fines so large "that companies risk going bankrupt," but Davis and Abraham fear that "courts might be reluctant to impose penalties that would threaten the survival of companies."

What is clear from Davis and Abraham's editorial is a belief that unethical and corrupt behaviour is "endemic" in the drug industry. "Individual instances of corporate malfeasance are indicative of wider systemic problems," they say.

The idea of a culture gone horribly wrong also emerges in the picture Heather Wood paints of Mid Staffordshire NHS Foundation Trust, the subject of the long awaited Francis report, which was published this week. Wood, who was lead investigator and author of the Health Commission report into Mid Staffs in 2009, writes in her Observations column (p 25): "The horrors of Stafford Hospital were failures of clinical care—but these were the symptoms, albeit deeply distressing, of a serious underlying illness. And that deep rooted pathology is the stranglehold that managers, many apparently devoid of an ethical code and certainly without a regulatory body, have on the NHS."

The Francis report was published too late for the *BMJ* to include detailed coverage of its recommendations in this week's print issue, but you will find it all on [bmj.com](http://bmj.com).

**Trevor Jackson, deputy editor, *BMJ***  
**[tjackson@bmj.com](mailto:tjackson@bmj.com)**

Cite this as: *BMJ* 2013;346:f777

## Email alerts

Busy? Little time to source information of direct relevance to you? Explore the range of email alerts from the *BMJ*'s table of contents, editor's choice, press releases, and others related to your medical specialty. You choose and get the alert delivered straight to your inbox.

Visit  
[bmj.com/email-alerts](http://bmj.com/email-alerts)



**BMJ**